Outlook Therapeutics

$1.78
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.23 (-11.44%) As of 7:26 PM UTC today

Why Robinhood?

You can buy or sell OTLK and other stocks, options, and ETFs commission-free!

About OTLK

Outlook Therapeutics, Inc. Common Stock, also called Outlook Therapeutics, is a clinical-stage biopharmaceutical company, which engages in the identification, development, manufacture, and commercialization of ONS-5010/LYTENAVA as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in South Brunswick, NJ. The listed name for OTLK is Outlook Therapeutics, Inc. Common Stock.

CEO
Lawrence A. Kenyon
Employees
8
Headquarters
South Brunswick, New Jersey
Founded
2010
Market Cap
310.67M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
2.33M
High Today
$2.04
Low Today
$1.71
Open Price
$1.99
Volume
2.96M
52 Week High
$4.26
52 Week Low
$0.499

OTLK Earnings

-$0.62
-$0.40
-$0.17
$0.05
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Estimated
— per share
Actual
Expected May 13, Pre-Market

You May Also Like

IEMG
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure